Literature DB >> 16136311

The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease.

Nuran Turkcapar1, Murat Toruner, Irfan Soykan, Olcay Tiryaki Aydintug, Hulya Cetinkaya, Nursen Duzgun, Ali Ozden, Murat Duman.   

Abstract

To determine the prevalence, clinical and radiological characteristics of spondyloarthropathy (SpA) in patients with inflammatory bowel disease (IBD), to assess the association between HLA B27 and B51 and the extraintestinal symptoms and to evaluate whether IBD is associated with Behçet's disease (BD). One hundred and sixty-two consecutive adult patients with established diagnosis of IBD as either Crohn's disease (CD) or ulcerative colitis (UC) were evaluated. All the patients including those previously diagnosed with or without SpA had a complete rheumatologic examination and they were evaluated according to the European Spondyloarthropathy Study Group (ESSG) criteria for SpA and The International Study Group for Behçet's disease criteria for BD. The demographic and clinical data were recorded on a standardized form. The radiographies were obtained in all the patients and computed tomography (CT) was performed in the patients with suspected pelvic radiographies and/or low back pain in the physical examination. Radiological evaluation was made according to the Modified New York criteria. HLA B27, B51 and anti-neutrophile cytoplasmic antigen (ANCA) were searched in all the patients. Of the 162 patients with IBD (mean age 41.48+/-11.63 years, male 60, female 102), 78 were CD and 84 were UC. The mean of the IBD duration was 54.92+/-50.32 months and SpA duration was 20.63+/-34.37 months. The prevalence of SpA and AS in IBD was 45.7 and 9.9%, respectively. Frequencies of SpA and AS, the difference between UC and CD were not significant. Spondylitis, enthesitis, peripheral arthritis, oral ulcer and uveitis were not different between UC and CD, but erythema nodosum was found significantly more common in the CD patients compared with UC patients (P=0.005). The duration of IBD and SpA was similar in both groups. As the IBD duration increased, the prevalence of SpA development decreased (rr=0.991, P=0.009). Of the IBD patients, 13.6% were asymptomatic for musculoskeletal manifestations of SpA and their sacroiliac radiographies and CTs showed grade 2 sacroiliitis. HLA B27, B51 and ANCA positivities were not different between the patients with UC and CD. HLA B27 was significantly more common in the patients with sacroiliitis, spondylitis, enthesitis, peripheral arthritis, erythema nodosum, uveitis (P<0.001) and oral ulcer (P=0.025). BD was diagnosed in none of the patients. ANCA positivity was found to be related with the presence of erythema nodosum and uveitis (P=0.001 and P=0.005). The prevalence of SpA and AS is higher in the prospectively evaluated patients with radiological studies than those in the previously published studies. There is a high prevalence of asymptomatic sacroiliitis in IBD. An early diagnosis of inflammatory arthritis in IBD patients may prevent a disability due to SpA and AS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136311     DOI: 10.1007/s00296-005-0044-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  30 in total

1.  Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.

Authors:  A Spoorenberg; D van der Heijde; E de Klerk; M Dougados; K de Vlam; H Mielants; H van der Tempel; S van der Linden
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

Review 2.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

3.  The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.

Authors:  C N Bernstein; J F Blanchard; P Rawsthorne; N Yu
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

4.  Delay in diagnosis of spondarthritis.

Authors:  B L Kidd; M I Cawley
Journal:  Br J Rheumatol       Date:  1988-06

5.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

6.  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.

Authors:  K de Vlam; H Mielants; C Cuvelier; F De Keyser; E M Veys; M De Vos
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

7.  Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease.

Authors:  Sophia Steer; Hugh Jones; Jane Hibbert; Elli Kondeatis; Robert Vaughan; Jeremy Sanderson; Terence Gibson
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

Review 8.  The role of gut inflammation in the pathogenesis of spondyloarthropathies.

Authors:  H Mielants; M De Vos; C Cuvelier; E M Veys
Journal:  Acta Clin Belg       Date:  1996       Impact factor: 1.264

9.  A weak association of HLA-B*2702 with Behçet's disease.

Authors:  A Gül; F A Uyar; M Inanç; L Ocal; J H Barrett; O Aral; M Koniçe; G Saruhan-Direskeneli
Journal:  Genes Immun       Date:  2002-09       Impact factor: 2.676

10.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10
View more
  40 in total

1.  Peripheral arthritis in the course of inflammatory bowel diseases.

Authors:  Ilhami Yüksel; Hilmi Ataseven; Omer Başar; Seyfettin Köklü; Ibrahim Ertuğrul; Aysel Ulker; Ulkü Dağlı; Nurgül Saşmaz
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

2.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

3.  Association between maternal inflammatory bowel disease and adverse perinatal outcomes.

Authors:  D Getahun; M J Fassett; G F Longstreth; C Koebnick; A M Langer-Gould; D Strickland; S J Jacobsen
Journal:  J Perinatol       Date:  2014-03-20       Impact factor: 2.521

4.  Diagnostic dilemma between intestinal Behçet disease and inflammatory bowel disease with pyoderma gangrenosum.

Authors:  Cem Evereklioglu
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

Review 5.  Spondyloarthritis and the microbiome: new insights from an ancient hypothesis.

Authors:  Julia Manasson; Jose U Scher
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

Review 6.  Autoantibodies and an immune-based rat model of inflammatory bowel disease.

Authors:  Hadi Esmaily; Yara Sanei; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.

Authors:  Dirk Elewaut; Filip Van den Bosch; Gust Verbruggen; Filip de Keyser; Bert Vander Cruyssen; Herman Mielants
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

Review 8.  Spondyloarthritis: clinical suspicion, diagnosis, and sports.

Authors:  Brock E Harper; John D Reveille
Journal:  Curr Sports Med Rep       Date:  2009 Jan-Feb       Impact factor: 1.733

9.  Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease.

Authors:  Carmen Stolwijk; Marieke Pierik; Robert Landewé; Ad Masclee; Astrid van Tubergen
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

Review 10.  Rheumatic manifestations of inflammatory bowel disease.

Authors:  Tatiana Sofía Rodríguez-Reyna; Cynthia Martínez-Reyes; Jesús Kazúo Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.